Gilead Sciences Inc. (GILD)
Gilead's Transition Into A Long-Duration Biotech Platform
Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune.
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago.
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) closed at $130.84 in the latest trading session, marking a +1.55% move from the prior day.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
